Protein Sciences and Passport Health team up on Flublok; MicroVAX begins cancer vax trial;

> Protein Sciences and Passport Health have teamed up to offer the Flublok flu vaccine at more than 230 Passport Health locations across the U.S. Release

> MicroVAX has begun a Phase I trial for its cancer vaccine platform for patients with breast, prostate, colon, ovary and lung cancers that have relapsed after initial therapy. Report

> In a U.K. study, researchers from the University of Southampton found that two new meningitis vaccines, Novartis' Menveo (MenACWY-CRM) and Bexsero (4CMenB), prevented the transmission of meningitis bacteria by up to 40%.

And Finally... Up to 30,000 people could have used experimental treatments or vaccines so far in the world's worst outbreak of Ebola, British scientists say. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.